Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AD16 in healthy adults
NCT05806177Phase 1Completed
- Sponsor
- South China Center for Innovative Pharmaceuticals
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing AD16 with Placebo (2 arms). Primary endpoints: Adverse events, Serious adverse events and 3 more. Started May 2020; status: completed.
02
Drugs
AD16
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05806177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806177.